We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Two Genes Linked to Common Types of Gliomas

By LabMedica International staff writers
Posted on 23 Feb 2009
Scientists have linked mutations in two genes, isocitrate dehydrogenase 1 (IDH1) and IDH2, to nearly three-quarters of several of the most common types of brain cancers known as gliomas.

Mutations were found by amplifying sections of the IDH1 and IDH2 genes through polymerase chain reaction (PCR), a process that replicated bits of DNA to levels that were detected by sensitive computer equipment. More...
IDH1 and IDH2 gene alterations were identified in material taken from 500 brain tumors and 500 non-central nervous system cancers. Changes in the IDH1 gene were located in more than 70 % of three common types of gliomas: low-grade astrocytomas, oligodendrogliomas, and secondary glioblastomas. The changes occurred within a single spot along a string of thousands of genetic coding letters. Some of the brain cancers that did not have alterations in IDH1 had equivalent mutations in the closely related gene, IDH2.

Investigators at the Johns Hopkins Kimmel Cancer Center (Baltimore, MD, USA) and Duke University Medical Center (Durham, NC, USA) who performed the study said that further examination of the genes could lead to more precise diagnosis and treatments of the gliomas.

"Pathologists may find it useful to determine IDH1/IDH2 status to help identify and classify these cancers," said D. Williams Parsons, M.D., Ph.D., visiting professor in pediatric oncology at Johns Hopkins and assistant professor at Baylor College of Medicine (Houston, TX, USA). He added that proper diagnosis is essential because treatments differ within types of gliomas, as well as other forms of brain cancer.

Related Links:

Johns Hopkins Kimmel Cancer Center
Duke University Medical Center
Baylor College of Medicine



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.